Neurocrine Biosciences, Inc. (NASDAQ:NBIX) insider Darin Lippoldt sold 9,900 shares of the business’s stock in a transaction that occurred on Wednesday, November 15th. The shares were sold at an average price of $73.05, for a total value of $723,195.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Neurocrine Biosciences, Inc. (NBIX) traded down $0.02 on Friday, reaching $72.28. The company’s stock had a trading volume of 864,771 shares, compared to its average volume of 1,122,800. The company has a current ratio of 14.38, a quick ratio of 14.37 and a debt-to-equity ratio of 1.05. Neurocrine Biosciences, Inc. has a one year low of $37.35 and a one year high of $75.98.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its earnings results on Wednesday, November 1st. The company reported ($0.13) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.49) by $0.36. The firm had revenue of $60.77 million for the quarter, compared to analysts’ expectations of $29.38 million. During the same quarter in the previous year, the firm posted ($0.43) earnings per share. equities analysts anticipate that Neurocrine Biosciences, Inc. will post -1.74 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This story was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another domain, it was illegally copied and republished in violation of US and international copyright and trademark law. The legal version of this story can be accessed at https://www.thecerbatgem.com/2017/11/18/neurocrine-biosciences-inc-nbix-insider-darin-lippoldt-sells-9900-shares-of-stock.html.

Institutional investors and hedge funds have recently bought and sold shares of the business. First Trust Advisors LP boosted its position in Neurocrine Biosciences by 29.0% during the third quarter. First Trust Advisors LP now owns 782,685 shares of the company’s stock worth $47,963,000 after purchasing an additional 176,136 shares in the last quarter. Canada Pension Plan Investment Board boosted its position in Neurocrine Biosciences by 49.7% during the second quarter. Canada Pension Plan Investment Board now owns 24,700 shares of the company’s stock worth $1,136,000 after purchasing an additional 8,200 shares in the last quarter. Artisan Partners Limited Partnership purchased a new stake in shares of Neurocrine Biosciences in the second quarter valued at $15,981,000. Davidson Kempner Capital Management LP purchased a new stake in shares of Neurocrine Biosciences in the second quarter valued at $3,639,000. Finally, California Public Employees Retirement System lifted its position in shares of Neurocrine Biosciences by 2.2% in the second quarter. California Public Employees Retirement System now owns 179,300 shares of the company’s stock valued at $8,248,000 after acquiring an additional 3,900 shares in the last quarter.

NBIX has been the topic of a number of recent research reports. BMO Capital Markets boosted their target price on Neurocrine Biosciences from $75.00 to $84.00 and gave the company an “outperform” rating in a report on Friday, August 4th. Cowen and Company reissued an “outperform” rating and issued a $65.00 target price (up previously from $60.00) on shares of Neurocrine Biosciences in a report on Wednesday, August 9th. BidaskClub raised Neurocrine Biosciences from a “hold” rating to a “buy” rating in a report on Wednesday, August 9th. Piper Jaffray Companies set a $68.00 price objective on Neurocrine Biosciences and gave the stock a “buy” rating in a report on Thursday, August 24th. Finally, ValuEngine raised Neurocrine Biosciences from a “sell” rating to a “hold” rating in a report on Friday, September 1st. One investment analyst has rated the stock with a hold rating and eighteen have given a buy rating to the company. The company has an average rating of “Buy” and an average price target of $78.88.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.

Insider Buying and Selling by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Stock Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related stocks with our FREE daily email newsletter.